Authors: | Molina, A. M.; Motzer, R. J.; Heng, D. Y. |
Article Title: | Systemic treatment options for untreated patients with metastatic clear cell renal cancer |
Abstract: | The introduction of therapy targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapomycin (mTOR) has significantly improved the outcome of patients with metastatic renal cancer. In this article a comprehensive overview of treatment choices for previously untreated patients with metastatic disease is given. Both established and emerging therapeutic options are discussed, as are prognostic factors predicting outcome. © 2013 Elsevier Inc. |
Keywords: | overall survival; fatigue; neutropenia; sorafenib; bevacizumab; sunitinib; diarrhea; drug safety; drug withdrawal; hypertension; monotherapy; systemic therapy; anorexia; cytoreductive surgery; progression free survival; quality of life; drug eruption; anemia; tumor volume; leukopenia; nausea; stomatitis; thrombocytopenia; vomiting; hypercalcemia; pyrimidines; kidney carcinoma; kidney neoplasms; nephrectomy; temsirolimus; asthenia; dyspnea; hyperglycemia; protein kinase inhibitors; karnofsky performance status; carcinoma, renal cell; sulfonamides; pazopanib; peripheral edema; hypercholesterolemia; axitinib; indoles; pyrroles; hand foot syndrome; kidney metastasis; proteinuria; hyperlipidemia; patient counseling; sirolimus; patient preference; randomized controlled trial (topic); recombinant alpha interferon; cancer prognosis; antibodies, monoclonal, humanized; tivozanib |
Journal Title: | Seminars in Oncology |
Volume: | 40 |
Issue: | 4 |
ISSN: | 0093-7754 |
Publisher: | Elsevier Inc. |
Date Published: | 2013-08-01 |
Start Page: | 436 |
End Page: | 443 |
Language: | English |
DOI: | 10.1053/j.seminoncol.2013.05.013 |
PROVIDER: | scopus |
PUBMED: | 23972707 |
DOI/URL: | |
Notes: | --- - Cited By (since 1996):1 - "Export Date: 1 October 2013" - "CODEN: SOLGA" - "Source: Scopus" |